Johnson & Johnson Accelerates Divestiture of Non-Core Businesses
Johnson & Johnson (JNJ) is continuing its strategy of divesting non-core businesses. The company plans to sell or spin off its orthopedic division, DePuy Synthes, in an effort to streamline its operations and focus on higher-margin, faster-growing healthcare businesses.
The move follows the 2023 spinoff of Kenvue, a consumer-focused business that was divested due to its slower growth compared to Johnson & Johnson's other medical device businesses. The company's goal is to become leaner, more profitable, and faster-growing, as Wall Street prefers companies with strong growth prospects.
Johnson & Johnson has begun discussing DePuy Synthes with potential buyers, including Apollo Global Management, which is reportedly considering a $20 billion acquisition of the division. Selling DePuy Synthes to Apollo would be a faster and cleaner path to divestiture compared to a spinoff, allowing Johnson & Johnson to focus on its core business.
The long-term benefit of this move lies in the potential for accelerated growth and improved profitability, as removing DePuy Synthes from the portfolio will allow Johnson & Johnson to concentrate on higher-margin markets.